- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07942571
Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study
Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil
This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.
Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.
Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.
Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.
A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Gustavo Subtil M. Freire, MSc
- Telefonnummer: +55 61 2028-5000
- E-post: gustavo.freire@ebserh.gov.br
Studieorter
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien
- Rekrytering
- Hospital Universitário Professor Edgard Santos (HUPES)
-
-
Federal District
-
Brasília, Federal District, Brasilien
- Rekrytering
- Hospital Universitário de Brasília (HUB)
-
-
Goiás
-
Goiânia, Goiás, Brasilien
- Rekrytering
- Hospital das Clínicas da UFG
-
-
Paraná
-
Curitiba, Paraná, Brasilien
- Rekrytering
- Hospital IPO - sede Água Verde
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien
- Rekrytering
- Hospital das Clínicas da UFPE
-
-
Piauí
-
Teresina, Piauí, Brasilien
- Rekrytering
- Hospital Getúlio Vargas (HGV)
-
-
Rio Grande do Sul
-
Canoas, Rio Grande do Sul, Brasilien
- Rekrytering
- Hospital Universitário Canoas
-
Porto Alegre, Rio Grande do Sul, Brasilien
- Rekrytering
- Hospital de Clínicas de Porto Alegre (HCPA)
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasilien
- Rekrytering
- Hospital Universitário Pedro Ernesto
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasilien
- Rekrytering
- Hospital das Clínicas da FMRP-USP - Campus
-
São Paulo, São Paulo, Brasilien
- Rekrytering
- Hospital das Clínicas da FMUSP
-
São Paulo, São Paulo, Brasilien
- Rekrytering
- Hospital São Paulo - Hospital Universitário da UNIFESP
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.
Beskrivning
Inclusion Criteria:
Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.
Ability to understand and complete the study assessments.
Exclusion Criteria:
Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: OTHER
- Tidsperspektiv: CROSS_SECTIONAL
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Sinonasal Disease Participants
Adults with chronic rhinosinusitis or other sinonasal diseases. |
|
Healthy Comparison Participants
Healthy adults without olfactory complaints. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
MultiScent-20 odor identification score
Tidsram: Once at enrollment (cross-sectional assessment).
|
Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance. |
Once at enrollment (cross-sectional assessment).
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sinonasal Outcome Test-22 (SNOT-22) total score
Tidsram: Once at enrollment (cross-sectional assessment).
|
Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden. |
Once at enrollment (cross-sectional assessment).
|
|
Severity of four sinonasal symptoms on visual analog scales
Tidsram: Once at enrollment (cross-sectional assessment).
|
Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified. |
Once at enrollment (cross-sectional assessment).
|
|
Nasal Polyp Score (NPS)
Tidsram: At enrollment, using available routine clinical assessment.
|
Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment. |
At enrollment, using available routine clinical assessment.
|
|
Lund-Mackay computed tomography score
Tidsram: At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available. |
At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
|
Peripheral blood eosinophil count
Tidsram: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Total serum immunoglobulin E (IgE)
Tidsram: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Total serum IgE concentration obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
Tidsram: Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria. |
Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
|
Presence of selected comorbidities
Tidsram: Once at enrollment (cross-sectional assessment).
|
Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history. |
Once at enrollment (cross-sectional assessment).
|
|
Number of previous sinonasal surgeries
Tidsram: Once at enrollment (cross-sectional assessment).
|
The number of previous sinonasal surgeries will be recorded for each participant. |
Once at enrollment (cross-sectional assessment).
|
|
Alcohol intolerance
Tidsram: Once at enrollment (cross-sectional assessment).
|
Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages. |
Once at enrollment (cross-sectional assessment).
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Gustavo Subtil M. Freire, University of Brasilia
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- UNB-OLFATO-RSC-2026
- 68687423.5.0000.5558 (Annan identifierare: Brazilian Research Ethics CAAE)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .